Unlearn’s scientists believe that it will be possible to use deep learning models to build quantitative, predictive models of all major biological phenomena. Along the way to solving that problem, Unlearn is working with pharma partners to build AI-driven digital twins of patients. It uses these twins to design more efficient and reliable clinical trials for specific indications.
News & Insights
Explore Companies
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules